CytomX Therapeutics Inc CTMX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.93
- Day Range
- $2.91–3.10
- 52-Week Range
- $1.72–8.21
- Bid/Ask
- $2.85 / $3.29
- Shares Outstanding
- 217.70M
- Market Cap
- $644.40M
- Volume/Avg
- 12 / 5M
Key Statistics
- Price/Earnings (Normalized)
- 87.62
- Price/Sales
- 13.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 69
- Website
- https://www.cytomx.com
Valuation
|
Metric
|
CTMX
|
|---|---|
Price/Earnings (Normalized) | 87.62 |
Price/Book Value | 2.05 |
Price/Sales | 13.59 |
Price/Cash Flow | — |
Price/Earnings
CTMX
Financial Strength
|
Metric
|
CTMX
|
|---|---|
Quick Ratio | 10.21 |
Current Ratio | 10.38 |
Interest Coverage | — |
Quick Ratio
CTMX
Profitability
|
Metric
|
CTMX
|
|---|---|
Return on Assets (Normalized) | −27.60% |
Return on Equity (Normalized) | −38.75% |
Return on Invested Capital (Normalized) | −40.46% |
Return on Assets
CTMX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Sqwg | — | |||
| Athersys Inc
ATHXQ
| — | Wywh | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vgqgvrjr | Jfbgvj | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zqmzwsbf | Qgxxd | $64B | |||
| UCB SA
UCBJF
| — | Swjm | $61B | |||
| UCB SA ADR
UCBJY
| — | Ptxvn | $61B | |||
| argenx SE
ARGNF
| — | Gdtqc | $56B | |||
| argenx SE ADR
ARGX
| Jyprrftl | Rlvw | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rzdtjbrv | Hdbnc | $38B | |||
| CSL Ltd
CMXHF
| — | Dytqwm | $36B |
United States